摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Cbz-(S)-3-氨基-2-羟基丙酸 | 42491-79-2

中文名称
Cbz-(S)-3-氨基-2-羟基丙酸
中文别名
——
英文名称
(2S)-3-{[(benzyloxy)carbonyl]amino}-2-hydroxypropanoic acid
英文别名
(S)-3-benzyloxycarbonylamino-2-hydroxypropionic acid;(S)-3-(benzyloxycarbonylamino)-2-hydroxypropanoic acid;3-benzyloxycarbonylamino-2-(S)-hydroxypropionic acid;S-β-(benzyloxycarbonylamino)-α-hydroxypropionic acid;(S)-N-benzyloxycarbonylisoserine;(2S)-2-hydroxy-3-(phenylmethoxycarbonylamino)propanoic acid
CAS
42491-79-2
化学式
C11H13NO5
mdl
——
分子量
239.228
InChiKey
GMWQKAHYINBSDJ-VIFPVBQESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    125-127 °C(Solv: acetone (67-64-1))
  • 沸点:
    494.5±45.0 °C(Predicted)
  • 密度:
    1.354±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    17
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    95.9
  • 氢给体数:
    3
  • 氢受体数:
    5

SDS

SDS:3125f01c0f8ba5925119bbabd6734c0a
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    Cbz-(S)-3-氨基-2-羟基丙酸 在 (R,R)-+BF4- lithium hydroxide 、 三氟化硼乙醚potassium tert-butylate氢气二异丁基氢化铝 作用下, 以 四氢呋喃甲醇乙醚正己烷异丙醇丙酮甲苯 为溶剂, -70.0~25.0 ℃ 、300.0 kPa 条件下, 反应 88.75h, 生成 (R)-3-benzyloxycarbonyl-5-<(S)-2-(tert-butoxycarbonylamino)-2-carboxyethyl>-2,2-dimethyl-1,3-oxazolidine
    参考文献:
    名称:
    Total Synthesis of the Biphenomycins; II.1Synthesis of Protected (2S,4R)-4-Hydroxyornithines
    摘要:
    已开发出用于制备三种不同保护的(2S,4R)-4-羟基鸟氨酸(10、16、24)的改进合成方法,这些方法显然可用于构建其他立体异构体。形成相应的α,β-二脱氢氨基酸衍生物(4、15、22)及其手性选择性氢化是这些合成过程的特征步骤。
    DOI:
    10.1055/s-1991-26480
  • 作为产物:
    参考文献:
    名称:
    Novel Glucagon Receptor Antagonists with Improved Selectivity over the Glucose-Dependent Insulinotropic Polypeptide Receptor
    摘要:
    Optimization of a new series of small molecule human glucagon receptor (hGluR) antagonists is described. In the process of optimizing glucagon receptor antagonists, we counter-screened against the closeli related human gastric inhibitory polypeptide receptor (hGIPR), and through structure activity analysis, we obtained compounds with low nanomolar affinities toward the hGluR, which were selective against the hGIPR and the human glucagon-like peptide-1 receptor (hGLP-1R). In the best cases, we obtained a >50 fold selectivity for the hGluR over the hGIPR and a > 1000 fold selectivity over the hGLP-1R. A potent and selective glucagon receptor antagonist was demonstrated to inhibit glucagon-induced glycogenolysis in primary rat hepatocytes as well as to lower glucagon-induced hyperolycemia in Sprague-Dawley rats. Furthermore. the compound was shown to lower blood glucose in the ob/ob mouse after oral dosing.
    DOI:
    10.1021/jm7015599
点击查看最新优质反应信息

文献信息

  • ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS
    申请人:Goldblum Adam Aaron
    公开号:US20120122809A1
    公开(公告)日:2012-05-17
    Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein Q 1 and Q 2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    揭示了具有抗菌活性的化合物。这些化合物具有以下结构(I):包括立体异构体、前药和其药用可接受的盐,其中Q1和Q2如本文所定义。还公开了与制备和使用这些化合物相关的方法,以及包含这些化合物的药物组合物。
  • New Convenient Reagents for Chemoselective <i>N</i>‐Alkoxycarbonylation of (<i>S</i>)‐Isoserine: Application in the Isepamicin Synthesis
    作者:Konstantin Doktorov、Velichko Tarpanov、Pepa Mechkarova
    DOI:10.1080/00397910701569320
    日期:2007.10.1
    Abstract A synthesis of a series of N‐alkoxycarbonyl mercaptobenzothiazoles (MBTs) and their application as reagents for chemoselective protection of amino group are presented herein. It was shown that all new reagents, Z‐MBT, Fmoc‐MBT, Phoc‐MBT, and Tec‐MBT, are highly effective in the selective N‐alkoxycarbonylation of (S)‐isoserine. The transformation is a simple, fast, and low‐cost protocol, which
    摘要 本文介绍了一系列 N-烷氧基羰基巯基苯并噻唑 (MBT) 的合成及其作为化学选择性保护基试剂的应用。结果表明,所有新试剂 Z-MBT、Fmoc-MBT、Phoc-MBT 和 Tec-MBT 在 (S)-异丝氨酸的选择性 N-烷氧基羰基化中都非常有效。该转换是一种简单、快速且低成本的协议,适用于放大实验。起始 MBT 在过程结束时完全回收,这是该方法的另一个优点。在基糖苷类抗生素异帕米星的合成中,庆大霉素 B 和 (S)-异丝氨酸在肽型偶联之前的选择性保护也证明了 Z 试剂的效率。
  • The preparation and biological activity of novel amino acid analogs of butirosin
    作者:T.H. Haskell、R. Rodebaugh、N. Plessas、D. Watson、R.D. Westland
    DOI:10.1016/s0008-6215(00)82782-2
    日期:1973.6
    of the aminocyclitol class of compounds to contain an amino acid in its chemical structure. Complete structural assignments for butirosin A and B have been described 2 and are shown in formula 1 . The amino acid, which is connected by an amide linkage to N 1 of the deoxystreptamine moiety, was found to be the unique ( S )-()-4-amino-2-hydroxybutyric acid 2 . The butirosins have marked activity against
    摘要基糖苷类抗生素butirosin(1)的氨基酸侧链已被化学修饰。通过四(5,5-二甲基-3-氧代-1-氧-1-环己烯-1-基)衍生物的碱解除去(S)-()-4-基-2-羟基丁酰基侧链。将得到的脱酰的三取代的衍生物3与多种单和多官能氨基酸再酰化。然后通过气除去环己烯基保护基,并通过色谱分离新的类似物。用包括绿假单胞菌在内的五种微生物确定了构效关系。鉴定出表现出针对假单胞菌的最大效力的特定侧链结构。Butirosin 1(一种新的基糖苷类抗生素复合物,由环状芽孢杆菌NRRL B-3312和B-3313的粘液状菌株产生,环醇类化合物的第一个实例是在其化学结构中包含氨基酸的化合物。Butirosin A和B的完整结构分配已在2中进行了描述,并在式1中显示。通过酰胺键连接到脱氧链胺基部分的N 1上的氨基酸被发现是独特的(S)-(-4-)-4-基-2-羟基丁酸2。Butiros
  • On the Asymmetric Induction in Proline-Catalyzed Aldol Reactions: Reagent-Controlled Addition Reactions of 2,2-Dimethyl-1,3-dioxane-5-one to Acyclic Chiral α-Branched Aldehydes
    作者:Jasna Marjanovic Trajkovic、Vesna Milanovic、Zorana Ferjancic、Radomir N. Saicic
    DOI:10.1002/ejoc.201701073
    日期:2017.11.9
    Proline-catalyzed aldol addition reactions of 2,2-dimethyl-1,3-dioxane-5-one to chiral aldehydes proceed under reagent stereocontrol (in both matched and mismatched cases) if aldehyde α-oxy or α-amino substituents are acyclic. For cyclic substituents, the stereochemical outcome of the aldolization in mismatched cases is difficult to predict.
    如果醛的α-氧基或α-基取代基是无环的,则在试剂立体控制下(在匹配和不匹配的情况下),脯酸催化的2,2-二甲基-1,3-二恶烷-5-酮与手性醛的羟醛加成反应。对于环状取代基,在不匹配的情况下醛醇缩合的立体化学结果很难预测。
  • Syntheses of 2′,3′-Dideoxykanamycin A, 2′,3′-Dideoxyamikacin and Related Substances
    作者:Yoshihiko Kobayashi、Tsutomu Tsuchiya、Sumio Umezawa、Toshio Yoneta、Shunzo Fukatsu、Hamao Umezawa
    DOI:10.1246/bcsj.60.713
    日期:1987.2
    2′,3′-Dideoxykanamycin A has been prepared via two ways. 2″-O-Acetyl-4″,6″-O-benzylidene-6′-N,4′-O-carbonyl-1,3,3″-tri-N-tosylkanamycin A was converted to a 2′,3′-unsaturated compound by a modified Tipson and Cohen method. Hydrogenation followed by deblocking gave 2′,3′-dideoxykanamycin A (12). Another route for 12 was through 2′,3′-anhydro-4′,2″,4″,6″-tetra-O-benzoyl-2′-epi-1,3,6′,3″-tetrakis(N-ethoxycarbonyl)kanamycin A (16). Epoxide-ring opening of 16 with hydrogen iodide gave the 3′,2′-iodohydrin, which, after 2′-O-mesylation, led to the 2′,3′-unsaturated compound (19). Deblocking and hydrogenation of 19 gave 12. 2′,3′-Dideoxykanamycin A thus synthesized was led to 2′,3′-dideoxyamikacin and other related compounds by amino protection of 12 other than the 1-amino group by zinc acetate–ethyl trifluoroacetate method followed by 1-N-acyl or 1-urethane formation with appropriate reagents. Their antibacterial activities were described.
    2′,3′-双脱氧卡那霉素A已通过两种方法制备。2″-O-乙酰基-4″,6″-O-苄叉-6′-N,4′-O-羰基-1,3,3″-三-N-甲苯磺酰卡那霉素A通过改良的Tipson和Cohen方法转化为2′,3′-不饱和化合物。随后进行氢化和脱保护,得到2′,3′-双脱氧卡那霉素A(12)。另一条途径是通过2′,3′-环氧-4′,2″,4″,6″-四-O-苯甲酰基-2′-表-1,3,6′,3″-四(N-乙氧羰基)卡那霉素A(16)进行。16与氢碘酸反应开环生成3′,2′-醇,经2′-O-甲磺酰化后,得到2′,3′-不饱和化合物(19)。19的脱保护和氢化得到12。合成的2′,3′-双脱氧卡那霉素A过乙酸-乙基三氟乙酸酯法保护除1-基外的其他基,随后用适当试剂形成1-N-酰基或1-氨基甲酸酯,进一步转化为2′,3′-双脱氧阿米卡星和其他相关化合物。描述了它们的抗菌活性。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫